CN101947312A - Modified polyethylene glycol superoxide dismutase (mPEG-SOD) nanoemulsion capable of being directly externally used for skin and preparation method thereof - Google Patents
Modified polyethylene glycol superoxide dismutase (mPEG-SOD) nanoemulsion capable of being directly externally used for skin and preparation method thereof Download PDFInfo
- Publication number
- CN101947312A CN101947312A CN 201010265116 CN201010265116A CN101947312A CN 101947312 A CN101947312 A CN 101947312A CN 201010265116 CN201010265116 CN 201010265116 CN 201010265116 A CN201010265116 A CN 201010265116A CN 101947312 A CN101947312 A CN 101947312A
- Authority
- CN
- China
- Prior art keywords
- sod
- mpeg
- emulsion
- superoxide dismutase
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 56
- 108010012938 polyethylene glycol-superoxide dismutase Proteins 0.000 title abstract description 11
- 239000007864 aqueous solution Substances 0.000 claims abstract description 17
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 11
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 8
- 229940046009 vitamin E Drugs 0.000 claims abstract description 8
- 239000011709 vitamin E Substances 0.000 claims abstract description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 274
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 274
- 230000006320 pegylation Effects 0.000 claims description 43
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 11
- 125000005456 glyceride group Chemical group 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 6
- 230000005291 magnetic effect Effects 0.000 claims description 5
- 238000003760 magnetic stirring Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000013019 agitation Methods 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 108010005555 monomethoxypolyethylene glycol-superoxide dismutase Proteins 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical class CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000037368 penetrate the skin Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 38
- 102000004190 Enzymes Human genes 0.000 description 29
- 108090000790 Enzymes Proteins 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 210000003491 skin Anatomy 0.000 description 26
- 239000010949 copper Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 21
- 238000011160 research Methods 0.000 description 21
- 239000001301 oxygen Substances 0.000 description 20
- 229910052760 oxygen Inorganic materials 0.000 description 20
- 230000006378 damage Effects 0.000 description 19
- 150000003254 radicals Chemical class 0.000 description 18
- 108010015479 superoxide dismutase-poly(styrene co-maleic acid butyl ester) Proteins 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 201000001320 Atherosclerosis Diseases 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 11
- 239000006071 cream Substances 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 102000009027 Albumins Human genes 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 9
- 101000836247 Aquifex pyrophilus Superoxide dismutase [Fe] Proteins 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 241001597008 Nomeidae Species 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- VJDVWBDSMDTODO-UHFFFAOYSA-N 2-methoxyethyl 4-amino-4-oxobutanoate Chemical compound COCCOC(=O)CCC(N)=O VJDVWBDSMDTODO-UHFFFAOYSA-N 0.000 description 8
- 208000023275 Autoimmune disease Diseases 0.000 description 8
- 208000018737 Parkinson disease Diseases 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 208000031225 myocardial ischemia Diseases 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 208000002177 Cataract Diseases 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000003448 neutrophilic effect Effects 0.000 description 6
- -1 polypropylene Polymers 0.000 description 6
- 230000002685 pulmonary effect Effects 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 230000031700 light absorption Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000005298 paramagnetic effect Effects 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 241000195493 Cryptophyta Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 201000008525 senile cataract Diseases 0.000 description 4
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- 229930195573 Amycin Natural products 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 3
- 206010048768 Dermatosis Diseases 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 3
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 108700004675 bleomycetin Proteins 0.000 description 3
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 238000005202 decontamination Methods 0.000 description 3
- 230000003588 decontaminative effect Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000010494 opalescence Effects 0.000 description 3
- 108010070915 orgotein Proteins 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000024806 Brain atrophy Diseases 0.000 description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000187481 Mycobacterium phlei Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003005 anticarcinogenic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960003291 chlorphenamine Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 238000007323 disproportionation reaction Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000001362 electron spin resonance spectrum Methods 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- PSFDQSOCUJVVGF-UHFFFAOYSA-N harman Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 210000003701 histiocyte Anatomy 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 229940055036 mycobacterium phlei Drugs 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000005408 paramagnetism Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 101150017120 sod gene Proteins 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BCJMVOVFCJGRAX-BTJKTKAUSA-N (z)-4-amino-4-oxobut-2-enoic acid;styrene Chemical compound C=CC1=CC=CC=C1.NC(=O)\C=C/C(O)=O BCJMVOVFCJGRAX-BTJKTKAUSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical group [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000589597 Paracoccus denitrificans Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 101000702641 Picea abies Superoxide dismutase [Cu-Zn], chloroplastic Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241001635574 Sabatia angularis Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010041303 Solar dermatitis Diseases 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000027515 Tracheal disease Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- NFGODEMQGQNUKK-UHFFFAOYSA-M [6-(diethylamino)-9-(2-octadecoxycarbonylphenyl)xanthen-3-ylidene]-diethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C21 NFGODEMQGQNUKK-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000006477 desulfuration reaction Methods 0.000 description 1
- 230000023556 desulfurization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 229960004534 orgotein Drugs 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 101150062190 sod1 gene Proteins 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses modified polyethylene glycol superoxide dismutase (mPEG-SOD) nanoemulsion capable of being directly externally used for skin and a preparation method thereof. The mPEG-SOD nanoemulsion is prepared from the following raw materials in part by weight: 7 parts of isopropyl myristate, 30 parts of caprylocaproyl macrogolglycerides, 10 parts of polyglyceryl-3-dioleate, 50 parts of mPEG-SOD aqueous solution and 3 parts of vitamin E. The mPEG-SOD nanoemulsion solves the problem that the SOD has low stability, is easy to deactivate, and has poor penetrability for external application to the skin. The modified polyethylene glycol superoxide dismutase (mPEG-SOD) nanoemulsion capable of being directly externally used for the skin is a preparation with good stability and capacity of persistently protecting the bioactivity of the SOD, and can quickly penetrate the skin so as to greatly improve the biological effect of the SOD. The preparation method has the advantages of simple preparation process, easy actual operation, no need of special instrument and equipment, and high-efficiency and quick preparation.
Description
Technical field
The invention belongs to medical technical field, but relate to Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a kind of direct cutaneous external and preparation method thereof.
Background technology
(1) general introduction of SOD
Since people such as nineteen sixty-eight American scholar McCord and Fridovich at first find and successfully extract superoxide dismutase (Superoxide Dismutase from ORBC, be called for short SOD) since, the research of SOD and application are subjected to the common concern of different in the world specialties, different subject research worker.People from different fields, different degree, different scopes, with diverse ways and means, the chemical nature of SOD, biological characteristics, molecular structure, pharmacology, medicineization and clinical, medical, chemical industry etc. are studied and are inquired into, and successfully set up a whole set of fast and effectively SOD separate and analytical method.Particularly people such as McMord in 1969 since having delivered about [biological significance of ultra-oxygen anion free radical and superoxide dismutase] on the biochemical magazine of the U.S., people are to free radical and biology, the relation of free radical and medical science, understanding is significantly improved, research has also had breakthrough, and the old and feeble free radical theory of professor's Harman proposition in 1956 is verified, replenish and developed. teach as Michelson and write in the symposium collected works preface of the French Banyuls that organized by European molecular biology association in June, 1976 (class's Reno this) first superoxides and superoxide dismutase: McMord in 1969 and Fridovich have at first found the SOD vigor and have delivered article about the biological significance of superoxide radical from the ox red blood cell; The following one by one a series of and creationary research work about the molecular biology aspect of oxygen metabolism since then almost can to deliver the result who causes after the famous dna double spiral structure theory comparable with nineteen fifty-three Watson and Crick. Comment that this section is penetrating is summarized and has been affirmed that SOD finds promoting important function and the value that the scientific research development is risen.
(2) SOD source, distribution and kind and basic characteristics thereof
SOD is a metalloid enzyme, and it extensively is present in all aerobic and aerotolerant each histiocytes of organism of nature.Since Cu.Zn-SOD, Mn-SOD, and the O that produces in the biological oxidation process is made in these three kinds of SOD isozyme debridements specifically of Fe-SOD
2In fact the cell that produces SOD had protection and protective effect to active oxygen; therefore; American scholar Keele imagination; all aerobic metabolism cells; comprise that the simplest microorganism all may contain SOD; really; people such as Yost 1973 successfully separate from E.Coli.B and have obtained Mn-SOD; and McCord in 1971 before this once carried out assay determination to more than 20 kind in nature to the SOD content in the different aerobe of oxygen demand, found that the aerobic metabolism of the existence of SOD and cell is closely related.SOD content in the anaerobe that usually can survive in air is lower than aerobic SOD slightly, and this may be through different relevant with contained oxygen demand and the generation active oxygen ability of different biologies.Up to the present, the specialty research worker has been separated from antibacterial, fungus, protozoacide, algae, insecticide, Fish, vegetable, beans, wild plant, crops (wheat, straw) and each internal organs of animal and histiocyte and has been obtained SOD, and these SOD that obtain are carried out further separation and purification and analysis and research backs confirms, these SOD mainly are divided into three types of Cu.Zn-SOD, Mn-SOD and Fe-SOD.
1.Cu.Zn-SOD: be the pale blue green, mainly be present in the eukaryotic cytoplasm, generally speaking, all have Cu.Zn-SOD in animal, plant, algae, microorganism and some the prokaryote body.Specifically, the main source of these enzymes has: people's (lung, brain, sperm, erythrocyte), horse (liver, erythrocyte), cattle (heart, liver, sperm, erythrocyte), sheep (liver, erythrocyte), pig (field, liver, kidney, erythrocyte), Canis familiaris L. (erythrocyte), chicken (liver, erythrocyte), duck (erythrocyte), goose (erythrocyte), arrow fish liver, the leaf of spinach, Plantula Brassicae chinensis leaf, Semen Phaseoli Vulgaris, Semen phaseoli radiati, Semen phaseoli radiati, straw, wheat, Mai Ye, Fructus Rosae Normalis, rose hip, Lentinus Edodes fungus, bakery yeast, beer yeast, slightly stick with paste neurospora etc.From these separate sources things, extract the Cu.Zn-SOD of purification, except that indivedual character differ greatly, other all have similar character, the Cu.Zn-SOD of these separate sources but, its pheron part is different with the kind source, amino acid whose arrangement preface along or form some differences still arranged, and this species diversity has just caused the non-identity on its enzyme biology and the physicochemical property again.
The basic characteristics of Cu.Zn-SOD show on its molecular weight and molecular weight subunit, molecular structure, aminoacid composition, electrophoretic property, spectral characteristic and electron paramagnetic resonance spectrum (EPR) etc.This enzyme molecular weight, except the enzyme molecular weight 135000 of purifying from lung, and have outside 4 subunits, the molecular weight of other sources Cu .Zn-SOD is all about 32000, the dimer that each is made up of two equal subunits, and all contain atom Cu and an atom Zn on each subunit.Behind polypropylene vinegar amine gel electrophoresis, protein staining and SOD vital staining clearly show the active region band of three enzymes, also present three enzymatic activity district bands after the isoelectrofocusing, the isoelectric point, IP of these three kinds of components is respectively 5.2,5.8,6.2, this enzyme has been located maximum light absorption at visible region 670nm (660-680nm), SOD concentrates in the absorption Spectrum characteristic of visible region, has reflected the optical characteristics of two copper ions in this enzyme prothetic group; (250~270nm) have located maximum light absorption, and at 280~320nm place certain light absorption are arranged, and the absorption Spectrum characteristic of its ultraviolet region is decided by certain amino acid whose content in this enzymatic structure albumen at this enzyme of ultraviolet region 265nm.Moreover, this enzyme also has a key property, it is paramagnetism, research and analysis prove, cupric has paramagnetism in the Cu.Zn-SOD molecule, just because of this reason, the Cu.Zn-SOD of oxidation state demonstrates distinctive electron paramagnetic wave spectrum, when being researched and analysed, the active center of Cu.Zn-SOD enzyme proves, the Cu.Zn-SOD activity not only is decided by pheron, but also is decided by prothetic group-Cu and Zn in this enzymatic structure, and further research discloses this enzyme amino acid composition, all contain a color amino in each Cu.Zn-SOD molecule, a methionine and three tyrosine residues, other is the highest with glycine content.This different aminoacids kind and content also are another important levy of this enzyme on molecular structure.
Need to prove that to the encode gene of Cu.Zn-SOD of the mankind, research worker is also furtherd investigate, the Cu.Zn-SOD that contains in verified higher mammal and the human Cytoplasm, its gene of encoding is positioned on the 21st pair of chromosome.
2.Mn-SOD: the Mn-SOD of separation and purification, be rose pink, be present in and remove in exo-erythrocytic all mitochondrions.Generally speaking, all have Mn-SOD in zooblast mitochondrion and the prokaryote body, specifically, the main source of these enzymes has: (1) eucaryotic organism comprises red algae, beer yeast, bakery yeast, Semen phaseoli radiati, Hepar Gallus domesticus, Hepar Mus, people liver, Cor Bovis seu Bubali etc.; (2) procaryote comprises escherichia coli (E.Coli.B), mycobacteria (mycobacterium lepraemurim, Mycobacterium phlei), bacillus stearothermophilus, spherical Rhodopseudomonas, the withered hot bacterium of streptococcus (fecal bacteria) (aquatic withered hot bacterium, have a liking for the withered hot bacterium of temperature), actinomycetes etc.; Though its source of these Mn-SOD is different, and very similar biological characteristics and physicochemical property are arranged, the different Mn-SOD in some source also exists some qualitative difference certainly.
The basic characteristics of Mn-SOD also mainly show on its molecular weight and molecular weight subunit, aminoacid composition, absorption spectrum, paramagnetic resonance spectrum method and enzymatic activity.Result of study shows, derive from the Mn-SOD in the prokaryotic cell, its molecular weight is mostly about 10000, except from Mycobacterium phlei, withered hot bacterium, the Mn-SOD that three kinds of cells such as actinomyces are purified is that the tetramer and mycobacteria are outside the trimer, the dimer that other is formed by two subunits, each subunit contains a manganese atom respectively, and derive from Mn-SOD in the eukaryotic cell mitochondrion, except the Mn-SOD that extracts from red algae is an aggressiveness of two subunits compositions, all the other all are the tetramers that four subunits are formed, its molecular weight is about 80000, and from molecular weight subunit, the Mn-SOD polypeptide chain is greater than Cu.Zn-SOD.The Mn-SOD of grain line body and algae or mushroom is in amino acid whose arrangement, though not exclusively roughly the same, but on the whole, similar, they and Cu.Zn-SOD are relatively, the most outstanding difference is that Cu.Zn-SOD only contains a tryptophan, and each subunit only has a tyrosine, and Mn-SOD contains more tyrosine and tryptophan.(473~480nm) have located maximum light absorption to this enzyme at visible region 475nm, but it is slightly variant with kind source difference, may be to decide by the state of charge of Mn-SOD is incomplete same, therefore, its oxidation or reduction all can influence visible absorption character, just for this reason, its extinction coefficient are different, and the optical absorption characteristics of performance is also different.Located similar general proteinic maximum light absorption peak at ultraviolet region 280nm (280-283nm), this ultra-violet absorption spectrum feature, may be because this enzyme contains the cause of the tyrosine and the tryptophan of a great deal of, its paramagnetic resonance characteristic, Mn-SOD and Cu.Zn-SOD are different, natural Mn-SOD does not have paramagnetic resonance spectrum, just show its paramagnetic resonance spectrum characteristic after having only the Mn-SOD degeneration, and it is identical by line with the resonance wave spectrum of MnCl2, the activity of this enzyme is relevant with Mn in the prothetic group, but its stable pheron that depends on.
The genetics research result confirms, contained Mn-SOD in the mitochondrion in higher mammal and the people's cell, and its gene of encoding it is positioned on the 6th pair of chromosome.
3.Fe-SOD: this enzyme is the same with Mn-SOD, Cu.Zn-SOD, all is that SOD has isozyme, its common effect characteristics, but all catalysis
Disproportionation is H
2O
2And O
2, but on many character and biological property, Fe-SOD is similar to Mn-SOD, and be not similar to Cu.Zn-SOD, and this may be different relevant with the source kind with the structure of three kinds of SOD isozymes.
It is faint yellow that Fe-SOD is, and such SOD exists only in the prokaryote.Specifically, these enzymes be mainly derived from prokaryote, as have a liking for the green bacterium of thiosulfate, the wine and women-sensual pursuits chomophoric bacterium, desulfurization vibrio, huge tooth born of the same parents bacillus, escherichia coli B, mycobacterium tuberculosis, Paracoccus denitrificans, luminous bacillus (comprising luminous bacillus at interval), knitline algae, ovum shape pseudomonas, cloud tongue etc., its molecular weight size is between Cu.Zn-SOD and Mn-SOD, about about 38000, most sources are that Fe-SOD is two dimers that equal subunit is formed, its Fe content is relevant with the source of this enzyme, the subunit that has has only the 1/2Fe atom, the subunit that has but has 1 Fe, because of it derives from some prokaryotic cells, the special more high animal and human's class of its race differs greatly, and is therefore, comparatively rare on Fe-SOD basis and clinic study center, practical application is rare especially, and this paper does not give unnecessary details.But what particularly point out is Fe-SOD catalysis
Reaction is secondary response, and its rate constant value increases with pH and descends, and under physics and chemical factor influence, the active normal bigger variation that takes place of Fe-SOD should be noted in the application especially.
(3) biological effect of SOD
SOD is that a class has the active high-molecular biologic enzyme of heigh antioxidation, its chemical nature remains protein, it has all characteristics of general enzyme, be equally living cells composition, produce the reactive protein that has the efficient catalytic function in vivo and in vitro by living cells.
In fact, why the global SOD that becomes famous receives much attention and favors, and not merely is because it is the achievement that U.S. scientist finds and succeeds in developing, and also be not only because it is the composition of living cells, but it can be by catalysis ultra-oxygen anion free radical (O
2) dismutation reaction takes place, alleviate or eliminate ultra-oxygen anion free radical (O
2) and metabolite or derivant the damage and the harm of inductive oxidation or peroxidation reply body.Particularly, SOD can effectively remove ultra-oxygen anion free radical as unique in the body
Enzyme-specific, the cofactor of nonprotein in its structure part or prothetic group are metal ion and exist with the metallo-chelate form.This special structure of SOD just makes it to because ultra-oxygen anion free radical
Inductive aging, inflammation, tumor, Radiation sickness, autoimmune disease, cardiac-cerebral ischemia pour into relevant diseases such as syndrome, cataract again and have good prevention effect, and SOD all has certain auxiliary curative effect to some sub-health status, cancer chemotherapy and radiotherapy, digestive system disease (chronic gastritis, atrophic gastritis etc.), respiratory system disease (asthma, bronchitis etc.), dermatosis (contact dermatitis, solar dermatitis, chloasma etc.), burn and reparation etc.Below the biological effectiveness of SOD is done simple an introduction.
1, the relation of SOD and inflammatory reaction: inflammation is a kind of protective response after body is subjected to the external microbe invasion.Phagocyte plays an important role in inflammatory reaction, and they produce respiratory burst in phagocytosis or irriate, consume oxygen, and activation pbosphohexose branch road discharges a large amount of
With OH isoreactivity oxygen, thus coup injury endotheliocyte, erythrocyte, fibroblast, platelet and sperm, the oxygen free radical injury that leukocyte itself also can be produced by it oneself.
As with the inductive pleuritis of SOD treatment carrageenin, can reduce hydrothorax and leukocytic accumulation.SOD can also suppress arthritis, reduces the precipitation of IgG at glomerule, disturbs the accumulation of leukocyte at glomerule inflammation position.SOD can suppress the change of the organ permeability that acute tracheitis that xanthine/xanthine oxidase causes causes, and reduces the accumulation of polymorphonuclear leukocyte in pulmonary, and SOD is used for the treatment of inflammation and has good application prospects.
LPS is the main stimulus object of bacterial inflammation, can induce the expression of many inflammatory factors (TNF-α, IL-1 etc.).Lu Andesi people such as (Loenders) utilizes the lps injection rat to cause pneumonia, finds that SOD combines with the epithelial cell of macrophage, neutrophilic granulocyte and trachea associated lymphoid tissue.At this moment, the SOD in the blood utilizes neutrophilic granulocyte as carrier, and it is transported to inflammation part, and SOD has the effect that phorbol ester is induced neutrophilic granulocyte and macrophage release free radical that suppresses.This shows that the neutrophilic granulocyte and the macrophage that combine SOD have the antagonism active oxygen, remove the autoprotection function of free radical.
Similar result of study also shows, SOD also can discharge cytokine by suppressing macrophage, weaken the neutrophilic granulocyte inflammation of LPS mediation, by weakening the migration of Langerhans cell to lymph node, the contact hypersensitivity that has significantly suppressed scytitis demonstrates anti-inflammatory, anti-infectious function that SOD has.And SOD also can weaken the acute inflammation that causes because of hyperoxia.
2, the relation of SOD and nervous system disease: FR induces oxidative stress and damage thereof to play a crucial role in many nervous system disease, and the normal antioxidation mechanism (comprising the effect of SOD) of brain may be very important to preventing these diseases.Zooscopy confirms that SOD can regulate the concentration of outer free radical of brain cell and peroxide, improves the cognitive function of brain.
For the brain atrophy patient, free radical (FR) or reactive oxygen species (ROS) can directly damage macromolecular substances in the brain cell, thereby cause cerebral tissue cell death widely.And at cerebral tissue gradually in the process of atrophy, outside antioxidation mechanism (comprising the effect of SOD) can make the effect of free radicals damage of continuous generation and be blocked.And SOD can play a significant role on the neural degree of necrosis after the minimizing brain atrophy.
There are dependency in SOD mutant and familial amyotrophic lateral sclerosis (AIS), and the SOD of sudden change can form nitric acid albumen with the pernitric acid reaction, finally causes the selectivity degeneration of motor neuron in the lateral sclerosis of spinal cord (AIS).Treatment to lateral sclerosis of spinal cord (AIS) can be adopted immunosuppressant, neurotrophic factor etc., but antioxidant SOD should be the most potential a kind of medicine.
The active detection of SOD finds that parkinson disease (PD) SOD in late period is active significantly to descend in the early stage and patients with terminal blood to parkinson disease (PD), and the damage of free-radical oxidation mechanism may be parkinson disease (PD) formation reason.And parkinson disease (PD) show that iron content changes in the brain, and mitochondrial function is impaired, and the anti-oxidation protection system weakens (minimizing that mainly is SOD and glutathion), so early stage SOD uses, should be a kind of very potential ancillary drug.
3, the relation of SOD and cardiovascular system diseases: SOD is expression in blood vessel wall, and mainly by the vascular smooth muscle cell secretion, it is the topmost existence form of SOD in the human aorta.SOD in the blood vessel mainly is present in the extracellular matrix, and other has sub-fraction in cell surface and blood plasma.
Superoxide radical
Inductive oxidative stress plays an important role and superoxide radical in the generation of atherosclerosis (AS), evolution
The whole process, particularly oxygen-derived free radicals that has also participated in cardiovascular disease generation, development is in the generation of the oxidative modification thing of low density lipoprotein, LDL (LDL) and play a part very crucial for the formation of atherosclerosis (AS).SOD can remove superoxide radical
, suppress or reduce lipid peroxide to form, alleviate peroxide injury, thereby the protection vascular system is avoided the damage of oxygen-derived free radicals, prevents the formation of atherosclerosis (AS) to vascular endothelial cell.
Research also shows, the expression decreased of SOD during coronary heart disease, and active reduction of SOD can be caused the disorder of patients with coronary heart disease blood vessel inner skin cell function.And, when atherosclerosis (AS), superoxide radical in the blood vessel
Also showed increased of generation, the superoxide radical that increases has simultaneously also disturbed neural adjusting to vascular tone.Therefore, improve SOD in the blood vessel expression can, to preventing the highest cardiovascular disease of human M ﹠ M significant.
In addition, SOD also can suppress
And the surplus balance in vivo of nitric oxide (NO), stop the generation and the development of atherosclerosis (AS).Simultaneously, regulate SOD with
Also significant with the active balance of NO to preventing and treating atherosclerosis (AS).
4, the relation of SOD and ischemical reperfusion injury:, when restoration of blood flow is logical again, cause the state of an illness further to worsen on the contrary in remissions such as bypass surgery coronarius, thrombolytic art, variant angina pectoris, coronary vasospasms.This be because, behind the myocardial ischemia-reperfusion
Producing increases, and passes through the lipid peroxidation injury of myocardium cell membrane of film, thereby causes Ca
2+Enter in a large number and produce arrhythmia in the cell.Simultaneously
Also energy loss blood trouble endothelial cell and myocardial cell inner mitochondria film, endoplasmic reticulum and lysosome membrane, thus the homergy of body destroyed, form the myocardial ischemia-reperfusion syndrome.At this moment, if just during this time inject the symptom that an amount of SOD can effectively alleviate " myocardial ischemia-reperfusion syndrome ", and if before recovering blood reperfusion, use SOD, even might prevent the appearance of " myocardial ischemia-reperfusion syndrome ".
Moreover, when myocardial ischemia-reperfusion, because
Generation increases, approach through the mediation of oxidative stress damaging action causes cardiac function to worsen, the existence and the exogenous SOD that gives of inherent antioxygen material may reduce the myocardial necrosis degree, reduce myocardial infarction area, and the reparation behind cardiac muscle and the blood vessel injury and function kept have positive effect.SOD except that being applied to the myocardial ischemia-reperfusion syndrome, also can be used for before the tremulous pulse ischemia-reperfusions such as brain, kidney, liver, small intestinal or refilling process among.
5, the relation of SOD and organ transplantation: organ transplantations such as liver, kidney, heart, skin, also exist the situation of recovering hemoperfusion, therefore, SOD also can be applicable to the syndrome that occurs in the operation processs such as the preservation of organs such as liver, kidney, heart, skin and transplanting, the replantation of amputated limb, shaping, beauty treatment, can alleviate the damage that free radical causes like this, guarantee the success of transplant operation.
By nanotechnology, sod gene is imported in the law during ischemia damage model mice body, make the interior SOD of liver increase nearly 10 times,
Eased down to normal level, the alanine aminotransferase level reduces, and hepatocellular ischemical reperfusion injury significantly reduces, this to liver transplantation after the protectiveness treatment significant.
6, the relation of SOD and pulmonary disease: SOD is free radical scavenger and a polyphenoils main in the lung tissue.Human SOD mainly is present in extracellular matrix, trachea and the alveolar gap of blood vessel.And the too much superoxide radical of pulmonary
Generate and destroy, can cause the generation of many pulmonary disease with the SOD balance.Therefore, the adjusting of antioxygen material such as SOD and replenish disease in control pulmonary and the many tracheal diseases very important.
Superoxide radical
Important medium when being acute lung injury, therefore polyphenoils such as increase or the raising SOD of pulmonary can be right
Inductive acute lung injury can be played effective protective effect.SOD also has the certain protection effect to some other diseases of pulmonary, can significantly protect it to avoid the pulmonary fibrosis damage that bleomycin causes as people SOD at the orientation expression of Mus pulmonary.
The scale-model investigation of adult's respiration inhibition syndrome (ARDS) confirms that neutrophilic granulocyte is excretory too much
The isoreactivity oxygen species has caused injury of lung, and makes that sb.'s illness took a turn for the worse.And in time, reasonable supplement SOD can effectively alleviate or reduce this type of injury of lung.Emphysema patient also can use SOD, but should not use when the pathological changes initial stage, the elastance of lung fiber suffered damage as yet, and curative effect is better.
7, SOD and autoimmune disease (auto immune disease, relation AID): the pathogenesis of various dissimilar autoimmune diseasees respectively has its different characteristics, but
Prostaglandin and the hydrolase that is generated by macrophage, monocyte and neutrophilic leukocyte play an important role on pathological changes.Moreover, superoxide radical
Oxidation and peroxide injury, can cause protein denaturation and protein synthesis mistake, thereby form autoimmune disease.Zoopery confirms that the scavenger of SOD and other oxygen-derived free radicals can suppress the chronic disease process of autoimmune disease, and SOD is by right
Scavenging action can prevent and treat all kinds of autoimmune diseasees.Can be used for treating lupus erythematosus, scleroderma, dermatomyositis etc. as SOD, demonstrate certain curative effect.Particularly for rheumatoid arthritis patients, as acute stage pathological changes do not form preceding use, its curative effect effect will be better.And, have among the human lupus erythematosus patients serum a kind ofly can make destructive Jie of chromosome split the factor, the existence of this factor with
Appearance is proportionate, so better with the SOD therapeutic effect.
8, SOD and Radiation sickness and radiation proof relation: radiation can cause that hydrone produces too much in the body
, and these too much generate
Cause the chain reaction of free radical, cause body right
Reaction increase the weight of, even form Radiation sickness.SOD can be used to prevent or treat the diseases such as cystitis, dermatomyositis, lupus erythematosus and leukopenia that cause owing to radiotherapy, and to being subjected to the personnel of ionizing radiation, also injectable SOD is as preventive measure.
9, senile cataract: the formation of senile cataract also mainly is superoxide radical
Result to the crystallin oxidation.Before senile cataract forms, perhaps in that to suffer from senile cataract early stage, even before entering the geratic period, promptly begin often to take some antioxidants, suitably replenish in other words and inject a certain amount of SOD, have certain prevention and initial stage therapeutic effect.If in case form cataract, then need surgical removal, fail to respond to any medical treatment with SOD.
(4) structural modification of SOD
SOD is a kind of special metalloenzyme, and the substrate of its effect is a ultra-oxygen anion free radical
The formation of ultra-oxygen anion free radical and a lot of diseases and substantial connection is arranged, its special role mechanism is subjected to the common concern of medical circle.As medicinal SOD, though still exclude pharmacopeia at present, existing abroad commodity selling, its commodity are Orgotein, Ormetein, Onotsein, Palosein, Paroxinorn.The development of the medicinal SOD preparation of compatriots and production develop rapidly, and some SOD preparations occur in succession, and through numerous scientists' cooperation, its basic medical research and clinical trial also enter certain phase.But,, poor with biomembranous affinity because free SOD half-life in blood is short, problems such as certain antigenicity are arranged, limited its extensive use clinically to a great extent, for this reason, research worker is stepped up research again both at home and abroad, and its molecular structure is transformed and modified.
1, Polyethylene Glycol-SOD (Polyethylene glycol-SOD, PEG-SOD) because free SOD half-life in blood is short, metabolic rate is soon in order to improve its clinical efficacy, people such as Mc.Cord developed the PEG-SOD derivant in 1979, they make PEG combine with free SOD with chemical method, make the PEG-SOD derivant, by assay determination, confirm that PEG-SOD extended to 24-35 hour than the half-life in the F-SOD blood by original 5-6 minute.Although PEG-SOD has strided forward major step aspect the half-life in prolonging blood, find that the holdup time of SOD and curative effect are not in full accord in the blood in research and the clinical practice, one of reason is the affinity problem of SOD and target cell.Because the affinity of PEG-SOD and target cell is low, curative effect is undesirable, so PEG-SOD fails to be promoted the use of clinically.But PEG-SOD is indubitable for the raising of SOD stability.
2, liposome-SOD (Liposome-SOD, L-SOD)
It is in the liposome of main component that people such as nineteen eighty-two Michelsion imbed SOD with phospholipid, makes liposome-SOD derivant.By analyzing and detecting and find that L-SOD can operate in the blood circulation well attached on the erythrocyte membrane, particularly SOD is to after going in the liposome to form L-SOD, it is not easy to decompose in blood, and molecular weight brings up to 9.6 ten thousand from 3.3 ten thousand, and the half-life extends to 7~24 hours.The author points out, the composition of the liposome by changing L-SOD can also obtain different organs is had the different SDO derivants of obvious tropism.For example, cationic liposome-SOD tends to lung more, and after anionic property liposome-SOD tended to liver, free SOD intravenous injection more, major part concentrated on kidney, L-SOD each internal organs that then can extensively distribute.The application of L-SOD on the animal pathological model is more, and as fibrosis cicatrix due to because of radiation, intramuscular injection just is clearly better for twice weekly.Usefulness low temperature such as Chan (50 ℃) cause rat brain infringement (edema, vascular permeability increase etc.), if before K cryogenic treatment, inject free SOD and L-SOD respectively to rat, found that, the rat of injection L-SOD, brain damage and edema and vascular permeability increase obviously alleviate, and free SOD is then invalid in injection.Treat some hepatopathy, autoimmune disease, rheumatism, kawasaki disease, Behcet disease and Crohn disease etc. in European and Japan with L-SOD and all obtain satisfactory effect.In addition, L-SOD and some anticarcinogen and usefulness can reduce its side effect, guarantee normal tissue cell.Bleomycin A5 for example, amycin, anticarcinogens such as daunomycin have produce the mechanism that active oxygen destroys the DNA chain in cancerous cell.In normal cell, the enzyme that decomposes bleomycin A5 is arranged, thereby it is less to Normocellular murder by poisoning, but myocardial cell lacks the enzyme that decomposes amycin and daunomycin, thereby they are big to the toxicity of cardiac muscle.Owing to entering the normal cell that comprises myocardial cell, L-SOD is difficult for entering cancerous cell, if with L-SOD and amycin, and daunomycin, bleomycin A5 merges use, both can bring into play its antitumaous effect, can reduce again cardiac muscle and Normocellular serious side effects.
Vein injects when dissociating SOD, and SOD is many attached to the cell outside, is difficult to enter in the cell.And during intravenous injection L-SOD, L-SOD can penetrate in the cell, on the sidewall attached to cell.The free SOD in the attached cell outside, it is right to bring into play in the cell
Scavenging action and Detoxication, can not bring into play Normocellular protective effect, on the contrary, also can influence and weaken cancer therapy drug destroying of cancerous cell subtracted effect; And enter in the cell, attached to the L-SOD of cell inwall, not only can reach free radical elimination effect in the born of the same parents, and can not disturb cancer therapy drug that cancerous cell subtracted effect extremely.Thereby, normal cell is protected, cancerous cell is subtracted extremely.Also have the author to propose, vein injects when dissociating SOD, blood level may of short durationly raise significantly, make free radical and free radical resisting concentration unbalance, both be unfavorable for the body homergy, also be unfavorable for the anti-mechanism of unloading of body, and after L-SOD enters cell, discharge free SOD on a small quantity lentamente, can not make concentration rising suddenly in the blood, the defense mechanism of body is not had influence.
3、SM-SOD
SM-SOD is meant the derivant (Stylenemleimide-SOD or Polytyrene-Comaleic acid-SOD write a Chinese character in simplified form SM-SOD) that styrene maleic amide and SDO form.During making, with maleic acid and styrene reaction, generate polystyrene maleic acid (SM) earlier, the latter is connected with SOD again, can form SM-SOD.Generally speaking, the Lys residue on the 1 molecule SOD molecule is connected with 2 molecule SM and amido link, forms SM-SOD.SOD molecular weight 3.3 ten thousand is not if be made into SM-SOD, after the intravenous injection, this hydrophilic protease is very fast to be removed by kidney, because, the behavior of undergraduate course class medicine in blood, the molecular size, form, charge property, the hydrophobicity that depend on them, the fine structure on surface and kidney are removed.Generally speaking, diameter is difficult for being removed by kidney the above person of 8nm.Albumin diameter 7nm, molecular weight (MW) about 6.6 sub-very much ovalizes are electronegative, with the protein of kidney basement membrane solution acid the electrostatic repulsion effect arranged, and renal function is just often difficultly removed by kidney.Yet, bilirubin, fatty acid, the carbamide equimolecular quantity is little more than the SOD molecular weight, but be difficult for being filtered by kidney, its reason is that these hydrophobic type aniones mainly become complex with albumin bound in blood, there is the scholar that this principle amplification is enlarged and is used for hydrophilic enzyme drug SOD, they select SM conduct and albumin and the bonded part of SOD, SM is combined formation SM-SOD derivant earlier with SOD, in the quiet injection body of SM-SOD, because SM can combine with albumin rapidly in vivo, therefore, after SM-SOD is injected into blood, the rapid and albumin bound of SM-SOD in blood.Generally whether molecule SM-SOD and molecule albumin bound, the SOD derivant of this albumin parcel can be by protease hydrolysis, and antibody contacts with it with leukocyte also difficulty, and this has not only protected the SOD enzyme not to be hydrolyzed destruction, and has reduced its antigenicity.SM-SOD-albumin complex is difficult for being removed by kidney, and the half-life extends to 6 hours in the blood.In addition, SM itself is protonated or become non-charged species, and fat-soluble raising is easy to combine with biomembrane.Molecular surface has the SOD (SM-SOD) of hydrophobic organic anion can assemble to the low diseased region of pH effectively in microcirculation, it is the focus tropism, this gathering is reversible, after pathological changes changes, SM-SOD returns in the blood and albumin bound again, form the white egg complex of SOD-SM-again, continue performance useful physiological function.The Japan scholar crosses limit letter and waits the people to report, the rat of myocardial ischemia-reperfusion, ventricular premature beat type arrhythmia phenomenon appearred after several seconds, if before ischemia-reperfusion respectively to free SOD of rat intravenous injection and SM-SOD, found that, arrhythmia does not appear in the rat of intravenous injection SM-SOD, the free then nonreactive rhythm of the heart effect of SOD of injection.This illustrates that also there are notable difference in SM-SOD and F-SOD on action effect.
4, enzymology-SOD (Acyl-SOD, simple Ac-SOD)
The SM-SOD half-life in vivo obviously prolongs, and certain focus tropism is arranged, and this is the strong point that SM-SOD uses in vivo.But the blood vessel in the tissues such as cornea, binding film, skin seldom or do not have, and provides the action effect of SOD little by intravasation and blood circulation to them, and SOD is electronegative lyoenzyme, with its eye dripping or be coated in skin, is difficult to be retained in diseased region.For this reason, Japanese scholar An Dong unit is just waiting the people to research and develop enzymology-SOD, hydrophobic fat acid is attached on the Lys residue of SOD molecule, makes it to form and the high Ac-SOD derivant of the double-deck affinity of cell membrane lipid.The SOD activity that Ac-SOD is active and environmental pollution is treated is roughly the same, but the affinity of Ac-SOD and film is strong, thereby can gather close the combination with cornea binding film, skin etc.Rabbit cornea inflammation or ulcer with Ac-SOD treatment endotoxin induced have obviously suppressed leukocyte infiltration, have delayed the development of pathological changes.And under similarity condition, adopt free SOD then not have this effect.
5, other modification SODs
Ctelan combines cattle Cu.Zn-SOD with glutaraldehyde, in blood again with albumin bound, forming molecular weight is 200000 dalton left and right sides derivants, the half-life extends to 6-8 hour in the blood.Gong Tian etc. combine the Mn-SOD of Serraria (Serratieae) with the protease of this bacterium, and then form α M-SOD derivant with people's α-macroglobulin, and the antigenicity of Serraria Mn-SOD is descended, and can keep its activity for a long time in the blood.
(5) SOD external preparation for skin situation
Descend since the good equality people in the little storehouse of Japanese scholar confirms in the tissue of dermatosis affected part that SOD is active, after LPO content raise, in recent years, department of dermatologry was specially learned this was carried out a large amount of research and discussion, now existing great mass of data report, and various skin is sick relevant with the SOD activity.
The research worker of Ningxia Medicine College has been measured the whole blood SOD activity of 4 patients and 21 members of family in two kinds of xeroderma pigmentosums (XP) family.The result shows: (1) XP patient's whole blood SOD activity is 1114.3 ± 80.0U/gHb; (2) heterozygous is 1224.9 ± 63.6U/gHb; (3) normal control group SOD activity of the same age is 1532.9 ± 31.00U/gHb and 1341.7 ± 78.7U/gHb.Patient's whole blood SOD activity is compared with matched group of the same age, and significance difference (P<0.05) is arranged.Heterozygous is compared with matched group of the same age, and difference does not have significance meaning (P>0.05).But from numerical value, its SOD activity really is lower than matched group of the same age, this group results suggest: SOD is active low in the morbidity of (1) XP and the patient's body,
By suppressing DNA repairase and dna polymerase activity, make DNA duplicate and repair process produces mistake, thereby and cause a series of clinical symptoms with DNA excision repair-deficiency person combined effect.(2) SOD-1 is active obviously low, and heterozygous SOD-1 activity is on the low side, show the DNA repair enzyme genetic relevant with primary disease may with SOD-1 gene linkage, be positioned on No. 21 chromosomes relevant.Therefore the author thinks, explore and use SOD preparation for treating XP patient, and may be a kind of comparatively effective method.
The author studies different SOD compound enzyme content to antihistaminic experiment, and selects chlorphenamine as the positive control medicine.Found that finite concentration and active SOD composite enzyme solution and chlorphenamine all can be to antihistaminics, and with very similar to antihistaminic circle, this shows that the application of SOD in the external preparation for skin medicine has certain theory and experiment basis.
About the diadermic problem of SOD, the author once selected three kinds of experimental animals (white mice, Cavia porcellus, rabbit) to test specially, one side is a control sides, smear and do not contain the SOD preparation: the same position of opposite side is a control sides, smear the same substrate that contains the SOD preparation, after one week, bark fetching undertissue measures the SOD activity respectively.The result shows that the test side subcutaneous tissue SOD activity that smears the SOD preparation is higher than matched group skin (P<0.01) very significantly, and a kind of result of experimental animal shows same rule.
The research worker of The 2nd Army Medical College basis Isotope Lab is in order to observe the Transdermal absorption situation of SOD-I, also carry out corresponding transdermal test, they smear for mouse back skin with 125I labelling human SOD (125I-Hsod-1) with the preparation of the aqueous solution of phosphate buffer, found that, 1h behind the skin, blood can be measured radioactivity 125I, and every ml blood counting reaches 500~600cpm, except that indivedual points, the radioactivity of blood cell all is higher than the radioactivity of blood plasma; The radioactive substance of each histoorgan also can be measured after skin is coated with 1h.So inference, SOD-1 can part enter body by skin.
In sum, SOD has medical value widely, but because natural SOD less stable, inactivation is difficult for preserving easily, and has limited the application surface of SOD.In recent years, more and more widely, its main cause comprises two aspects to SOD in the application on the skin care item, the one, and cosmetics additive can prevent skin aging, plays skin effect; The 2nd, the prevention and treat relevant dermatosis.These have at home and abroad obtained to use widely, and many superior cosmetics have all added SOD, and it is made facial film, milk, cream.Domestic have a not product such as old frost of big precious SOD frost, violet SOD frost and SOD.But the stability of SOD still becomes a big bottleneck of application, in some cosmetics for external use, mainly be by drug administration carrier, optimize the stability that preservation condition is come enhancement of SOD at present, avoid its inactivation, as using SOD external-use liposome cream treatment mottle clinically, obtain very big success.Zhang Huailiang adopts lecithin, cholesterol to prepare the carrier of liposome as SOD, studies show that the SOD activity can preserve more than 6 months in cream.
Carry out the research work of the chemical modification of a large amount of SOD in China, and obtained good result.Chemical modification be exactly on molecular level the group to SOD be connected with some biocompatibility macromole by artificial method, thereby reach the character that changes SOD, improve its half-life, reduce immunogenicity, weaken the hydrolysis of protease.Such as SOD with monomethyl Polyethylene Glycol (mPEG) modified, have less, the less enzyme degradation of stronger biological activity, loss of activity still less, longer half-life, blood concentration fluctuation, less immunogenicity and antigenicity, less toxicity, better dissolubility, etc.
Though to a certain extent, improved the stability of SOD, remedied a lot of defectives in the SOD application by chemical modification.But in the application of SOD percutaneous drug delivery, the skin permeation rate of SOD is too low, can only part enter body by skin, is difficult to reach the effect of treatment.So on using, the SOD permeability remains the problem of a key on the external preparation for skin.
Summary of the invention
The objective of the invention is, propose a kind of have stable good, but can protect the SOD biological activity lastingly and improve Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion and preparation method thereof of a kind of direct cutaneous external of SOD external preparation for skin permeability.
Because the nano-emulsion carrier belongs to the nanoscale emulsion, the first, can be wrapped in the SOD of modified in the nano-emulsion, further improve the stability of SOD composition; The second, the nano-emulsion carrier improved functional component dispersion, make functional component be present in the system with nanoscale, improved the transdermal penetration of SOD at the external preparation for skin product, maximization improves the utilization rate of functional component.The 3rd, the SOD that uses Pegylation is as the external functional component, and combining nano breast carrier formation mPEG-SOD nano-emulsion, has very much the external advantage.
But the purpose that realizes foregoing invention provides a kind of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of direct cutaneous external.
1, technical scheme of the present invention
(1) but Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a kind of direct cutaneous external of the present invention form by the following weight parts proportion raw material:
Isopropyl myristate 5-10 part
Sad capric acid polyethyleneglycol glyceride 25-35 part
Polyglycereol-3-dioleate 6-15 part
MPEG-SOD aqueous solution 46-53 part
Vitamin E 1-10 part
(2) but Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a kind of direct cutaneous external of the present invention form by the following weight parts proportion raw material:
Isopropyl myristate 6-8 part
Sad capric acid polyethyleneglycol glyceride 28-33 part
Polyglycereol-3-dioleate 7-12 part
MPEG-SOD aqueous solution 47-51 part
Vitamin E 2-6 part
(3) preferred weight part proportioning of the present invention is:
7 parts of isopropyl myristates
30 parts of sad capric acid polyethyleneglycol glyceride
10 parts of polyglycereol-3-dioleate
50 parts of mPEG-SOD aqueous solutions
3 parts of vitamin Es
(4) but Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a kind of direct cutaneous external of the present invention, the mass concentration of SOD aqueous solution is 0.03% in its prescription.
(5) but another object of the present invention provides a kind of preparation method of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of direct cutaneous external, may further comprise the steps:
1) mPEG-SOD with recipe quantity is dissolved in distilled water, and this solution is as the mPEG-SOD aqueous solution, standby;
2) take by weighing consumption according to each component ratio in the prescription, standby, the weight vitamin E of recipe quantity is dissolved in the isopropyl myristate, standby;
3) with the sad capric acid polyethyleneglycol glyceride of recipe quantity, polyglycereol-3-dioleate, the mPEG-SOD aqueous solution of fully mix homogeneously, and adding recipe quantity adds the liquid for preparing in (2) then;
And with whole system under 25 ℃ of conditions of room temperature or in the natural room temperature, start the time constant-temperature magnetic stirring apparatus, with 200rpmmin
-1The rotating speed magnetic agitation, fully mixing is transparence liquid until whole system, but is a kind of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of direct cutaneous external;
4) but Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of this a kind of direct cutaneous external is sub-packed in rapidly among the lucifuge glass container of different size, add a cover packing, and place 4 ℃ of airtight preservations of refrigerator to get final product rapidly.
2, beneficial effect of the present invention
But Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a kind of direct cutaneous external of the present invention in sum is compared with prior art, has following beneficial effect:
(1) SOD is after mPEG modifies, and promptly after the PEGization, its main biological function remains unchanged, also has following advantage: prolonged the half-life of SOD, increased the water solublity of SOD, reduced malicious pair and make sheet, reduce immunogenicity, improve medicine stability in vivo and in vitro.On this basis, but the present invention uses the nano-emulsion technology to prepare a kind of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of direct cutaneous external.Strengthened the advantage of mPEG-SOD further.
(2) but Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a kind of direct cutaneous external of the present invention, the nano-emulsion particle diameter is little, superoxide dismutase (SOD) dispersion that is contained improves, in external preparation for skin, can promote the Transdermal absorption of superoxide dismutase (SOD), solve the low problem of superoxide dismutase (SOD) preparation capable of permeating skin absorbance.
(3) but the present invention prepares a kind of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of direct cutaneous external, mPEG itself modifies the SOD structure, improved the stability of SOD, the special construction of adding nano-emulsion is wrapped in mPEG-SOD albumen in the nanometer nodule in the breast, does not contact with external environment.Nano-emulsion carrier itself has necessarily antibiotic, bacteriostasis in addition, just can not prevent product rotten so need not add chemical preservative, and this has further improved the stability of mPEG-SOD.
(4) but Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a kind of direct cutaneous external of the present invention preparation is to prepare under temperature conditions Celsius about 25 ℃, therefore activity and the content for protection SOD functional component has important value.The present invention can keep its biological activity and biological action to greatest extent.
(5) this product preparation process is simple, and practical operation is easy, preparation efficiently fast, does not need special instruments and equipment, and energy savings and cost are free from environmental pollution again, are fit to industrialization production.
3, preparation points for attention of the present invention
(1) product used container of when preparation must strictly according to the rules clean and sterilization, and preferably adopt strong acid to soak back water and dash, clear water washes clean again, dry with distilled water immersion the back, places after the baking oven high-temperature sterilization drying standby again; In addition, when carrying out the product preparation, used container all will be paid special attention to prevent to contain impurity or pollutions such as metal ion and microorganism, in order to avoid influence product quality and stability.
(2) SOD is the private present of the auspicious professor in Dinke, therefore, modifies and should in time link up with the fourth professor during preparation and get in touch in early stage, and is synthetic and prepare so that this seminar can finish the SOD of q.s.
(3) prepare in strict accordance with above-mentioned dosage and method.When carrying out this product preparation, should add according to above-mentioned flow sequence, its additive capacity must require accurate, and, in the interpolation of other raw material, could add a kind of raw material down after must waiting a kind of raw material of adding fully to dissolve again,, influence the preparation of whole nano-emulsion system in order to avoid occur muddyly.
(4) when preparation external mPEG-SOD nano-emulsion, need select and definite S/C mass ratio (km value), and definite S/C mass ratio (km value) 1,2,3,4, be to carry out the oily biphase binary liquid test of titration water and last definite by ability after the pseudo-ternary phase diagram analysis, only, be only comparatively ideal km value determining and calculating the km value that obtains maximum nano-emulsion zone.Above-mentioned preparation method determines that by testing Km value has been 3, but actual when carrying out the product preparation, surfactant (S) and cosurfactant in this ratio still must be after mixing also will be more abundant mixing, prepare effect and quality in order to avoid influence.
(5) because the proportion or the different relation of density of liquid solution, when carrying out the product preparation, the capacity of selected preparation container must be a bit larger tham the product volume of actual preparation, as prepare the 100g product, need to select the preparation container of 150-200mL, so both be convenient to each composition and fully mixed and dissolve, and also be convenient to ultrasonic concussion or stirring and evenly mixing, and be unlikely to overflow outward.
(6) though blank nano-emulsion itself has the characteristics of certain bacteria growing inhibiting, other interpolation antiseptic is not arranged in this formula for a product, so when carrying out the product preparation, except that the preparation container must carry out strictness cleaning and sterilization, also should be during concrete the preparation in strict accordance with rule of operation, under aseptic condition and according to the sterile working, require to operate as far as possible, avoid this nano-emulsion sample to be polluted, influence product quality.
(7) preparing the sample of finishing must pack with lucifuge, and places shady and cool dry ventilation lucifugal place to preserve as far as possible, keep fire away or thermal source.In addition, after product uses at ordinary times, need not place low temperature or refrigerator to preserve, but must seal tightly, be positioned over natural room temperature and keep in Dark Place and get final product.
(8) this product may have zest to skin, please suspends use immediately as using the position significant reaction to occur; In actual use, be sure not this product is done into ophthalmic; Skin is injured, have wound or redness must not use, use the back red and swollen if any continuing, and should stop using; Baby and child must not use; The skin sensitivity person should do the skin sensitivity property testing before using, and tests completely without irritative response and can use.
(9) SOD is a peptide matters, so-20 ℃ of left and right sides cold preservations of these solid feed needs are comparatively suitable, face with facing and join, and each amount of preparation should not be too big, and is now with the current as far as possible behind the preparation SOD aqueous solution, as toos many or too much for use, and should place 2-8 ℃ of refrigerator short-term to preserve.
(10) the mPEG-SOD nano-emulsion muddiness can occur after putting into refrigerator, but recovers can form nano-emulsion voluntarily after the room temperature, does not influence use.
Description of drawings
But Fig. 1. a kind of preparation technology's flow process and technology path of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of direct cutaneous external.
The specific embodiment
Further specify product of the present invention and preparation method below in conjunction with specific embodiment
Embodiment 1: but a kind of preparation method of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of direct cutaneous external
But a kind of preferred weight part proportioning of each raw material of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of direct cutaneous external is:
7 parts of isopropyl myristates
30 parts of sad capric acid polyethyleneglycol glyceride
10 parts of polyglycereol-3-dioleate
50 parts of mPEG-SOD aqueous solutions
3 parts of vitamin Es
But a kind of concrete preparation method of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of direct cutaneous external (100g is an example with preparation):
1. mPEG-SOD aqueous solution preparation: 0.015g mPEG-SOD is dissolved in the 49.985g distilled water.With this solution as water (I) 50g;
2. accurately take by weighing the isopropyl myristate of 7g with analytical balance, place another, and the vitamin E that takes by weighing 3g is dissolved in wherein, with clear oil phase (II) 10g that is labeled as of marking pen through among 50mL conical flask of decontamination;
3. according to the sad capric acid polyethyleneglycol glyceride (S) that has designed in advance: the ratio of polyglycereol-3-dioleate (C)=3: 1, accurately take by weighing the sad capric acid polyethyleneglycol glyceride of 30g and 10g polyglycereol-3-dioleate respectively, and the two raw material is placed among the clean conical flask of 100mL of the 3rd process decontamination; Add a cover, and this conical flask placed rapidly on the liquid flash mixer, open the liquid flash mixer, and it is transferred to the II shelves, fully mix homogeneously makes it to form emulsifying agent/co-emulsifier (S/C) mixture, behind the 3-5min, the closing liquid flash mixer takes off conical flask, and with clear S/C mixture (III) 40g that is labeled as of marking pen;
4. according to oil phase (II): S/C mixture (III): the ratio of water (I)=10%: 40%: 50%, fetch water respectively earlier phase (I) 50g, S/C mixture (III) 40g place among the 4th the clean conical flask of the 200mL through decontamination;
5. after above-mentioned water (I), S/C mixture (III) two liquid phases fully being mixed, again under 25 ℃ of conditions of room temperature or in the natural room temperature, put it into and shake in the ultrasonator also about ultrasonic 2min, perhaps under 25 ℃ of conditions of room temperature or in the natural room temperature, start the time constant-temperature magnetic stirring apparatus, with 200rpmmin
-1Rotating speed magnetic agitation 5min, then, in this container, directly add oil phase (II) 10g again, and with whole system in ultrasonator about ultrasonic 5min, perhaps under 25 ℃ of conditions of room temperature or in the natural room temperature, start the time constant-temperature magnetic stirring apparatus, with 200rpmmin
-1Rotating speed magnetic agitation 20min;
6. close ultrasonator or time constant-temperature magnetic stirring apparatus, take off the 200mL conical flask, observe its outward appearance limpid in this way colourless, fluidity and good dispersion, obviously visible opalescence person is arranged, but be Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a 100g direct cutaneous external;
7. but Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of this 100g direct cutaneous external is sub-packed in rapidly among the lucifuge glass container of different size, adds a cover rapidly, packing, and place 4 ℃ of airtight preservations of refrigerator to get final product;
8. according to International or National or enterprise's relevant criterion and requirement, stochastic sampling from above-mentioned packing product, at first adopt the distribution of particles and the size of this nano-emulsion sample of Ma Erwen instrument detecting, after meeting the quality standard of nano-emulsion, according to the specific requirement of national departments concerned, the system that carries out index of correlation detects again; After waiting to judge or estimating it and meet national relevant regulations and standard and authentication code fully, can be used as promptly that launch is sold or special-purpose in the beauty parlor.
Test example 1, evaluation of the present invention and study on the stability
The present invention detects by ultramicroscope, but a kind of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion outward appearance clear of direct cutaneous external, visible opalescence, has certain fluidity, and droplet diameter distribution is between 10~100nm.Thermodynamic stability of the present invention is good, and stable storage is good, by room temperature keep sample investigation, strong illumination experiment, hot test and low-temperature test, finds that the present invention is not stratified, even also not stratified in the high speed centrifugation environment.
1) the naked eyes outward appearance is observed: but a kind of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion outward appearance clear of direct cutaneous external, visible opalescence, have certain fluidity.Detect through transmission electron microscope, droplet diameter distribution is between 10~100nm.
2) temperature stability experiment:
But Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a kind of direct cutaneous external of the present invention is packed in the hermetic container, place under 4 ℃, 25 ℃, 40 ℃, the 60 ℃ conditions and investigate, press certain hour (0,1,3,6,12,24 month) at interval, measure study on the stability project (having or not layering).The result shows that mPEG-SOD nano-emulsion outward appearance of the present invention is still transparent, does not find muddiness or deposited phenomenon.
3) light stability experiment: but Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a kind of direct cutaneous external of the present invention is packed in the hermetic container, place under the daylight, light at room temperature is according to measuring in the 5th day, the tenth day, and the result does not relatively have difference before placing.Found that outward appearance of the present invention is still transparent, do not find muddy or precipitation, good stability is described.
4) accelerated stability experiment: but get Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a kind of direct cutaneous external of the present invention, place high speed centrifuge supporting centrifuge tube, with 13000rpmmin
-1The centrifugal 30min of speed, do not have layering, still transparent, illustrate that this product stability is good.
But the bioactive test of SOD in Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of test example 2, a kind of direct cutaneous external of the present invention
But prepare a kind of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of direct cutaneous external and traditional mPEG-SOD cream frost preparation method according to the present invention, under identical condition, prescription effective component of the present invention is mixed with mPEG-SOD nano-emulsion and mPEG-SOD cream frost respectively, under identical storage condition, measure the SOD activity respectively respectively at placing 30 days front and back, found that, but the SOD activity in a kind of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of direct cutaneous external is active obviously high than the SOD in the SOD cream frost.
But Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of test example 3, a kind of direct cutaneous external, cream frost, emulsion preparations transdermal test in vitro infiltration comparative experiments
But carry out a kind of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion, cream frost, emulsion preparations transdermal test in vitro infiltration comparative experiments of direct cutaneous external with the Franz diffusion cell.The Franz diffusion cell keeps 37 ℃ of water-baths, and with rat skin fixed supply pond with accept between the pond, corium is towards accepting the pond, and effectively infiltrating area is 5cm
2, accept to fill with acceptable solution in the pond, prevent to produce bubble, accepting pool volume is 10mL, to prepare mPEG-SOD nano-emulsion, mPEG-SOD cream frost, mPEG-SOD Emulsion 0.5g respectively and be uniformly coated on the skin for each three parts, place coverslip on the Supply House, prevent water evaporates.Open magnetic stirrer with 300r.min
-1Rotating speed stirs, and respectively at 1,2,4,6,9h takes out acceptable solution 1mL (the sampling back replenishes the equal-volume acceptable solution), with sample solution 15000r.min
-1Get supernatant behind the high speed centrifugation and carry out the HPLC analysis.Try to achieve each dosage form of SOD accumulative total Transdermal absorption amount by accumulation Transdermal absorption amount Q (formula 1), but calculate again the direct cutaneous external Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion, cream frost,
The transdermal test in vitro permeability such as the following table of emulsion preparations.
The dermal osmosis speed of mPEG-SOD nano-emulsion is respectively mPEG-SOD Emulsion and mPEG-SOD cream frost 1.36 and 1.65 times as can be known.The Franz diffusion cell is widely used in the transdermal test in vitro permeability test of medicine at present, and it can comparison image simulation medicine release conditions in vivo, has great importance for Study of Clinical Application.But medicine actual release conditions in vivo still is that some is different in the Franz diffusion cell with it.The result of study of Franz diffusion cell has important directive significance for people, but can not ignore the difference of it and truth.
Claims (6)
1. but Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a direct cutaneous external is characterized in that it is made up of the following weight parts proportion raw material:
Isopropyl myristate 5-10 part
Sad capric acid polyethyleneglycol glyceride 25-35 part
Polyglycereol-3-dioleate 6-15 part
MPEG-SOD aqueous solution 46-53 part
Vitamin E 1-10 part.
2. but Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a kind of direct cutaneous external according to claim 1 is characterized in that it is made up of following preferred weight part proportion raw material:
Isopropyl myristate 6-8 part
Sad capric acid polyethyleneglycol glyceride 28-33 part
Polyglycereol-3-dioleate 7-12 part
MPEG-SOD aqueous solution 47-51 part
Vitamin E 2-6 part.
But 3. Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a kind of direct cutaneous external according to claim 1, wherein preferred weight part proportioning of each raw material is:
7 parts of isopropyl myristates
30 parts of sad capric acid polyethyleneglycol glyceride
10 parts of polyglycereol-3-dioleate
50 parts of mPEG-SOD aqueous solutions
3 parts of vitamin Es.
4. but, it is characterized in that in the composition that the mass concentration of mPEG-SOD is 0.03% in the mPEG-SOD aqueous solution according to Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of claim 1,2,3 described a kind of direct cutaneous externals.
But 5. Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a kind of direct cutaneous external according to claim 3, but it is characterized in that the preparation method of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of described a kind of direct cutaneous external may further comprise the steps:
(1) mPEG-SOD with recipe quantity is dissolved in distilled water, and this solution is as the mPEG-SOD aqueous solution, standby;
(2) take by weighing consumption according to each component ratio in the prescription, standby, the weight vitamin E of recipe quantity is dissolved in the isopropyl myristate, standby;
(3) with the sad capric acid polyethyleneglycol glyceride of recipe quantity, polyglycereol-3-dioleate, the mPEG-SOD aqueous solution of fully mix homogeneously, and adding recipe quantity adds the liquid for preparing in (2) then;
And with whole system under 25 ℃ of conditions of room temperature or in the natural room temperature, start the time constant-temperature magnetic stirring apparatus, with 200rpmmin
-1The rotating speed magnetic agitation, fully mixing is transparence liquid until whole system, but is a kind of Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of direct cutaneous external;
(4) but Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of this a kind of direct cutaneous external is sub-packed in rapidly among the lucifuge glass container of different size, add a cover packing, and place 4 ℃ of airtight preservations of refrigerator to get final product rapidly.
6. but Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion of a kind of direct cutaneous external according to claim 5, but the average droplet size that it is characterized in that Pegylation superoxide dismutase (mPEG-SOD) nano-emulsion by the prepared a kind of direct cutaneous external of claim 5 method is in the scope of 10~100nm.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010265116XA CN101947312B (en) | 2010-08-26 | 2010-08-26 | Modified polyethylene glycol superoxide dismutase (mPEG-SOD) nanoemulsion capable of being directly externally used for skin and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010265116XA CN101947312B (en) | 2010-08-26 | 2010-08-26 | Modified polyethylene glycol superoxide dismutase (mPEG-SOD) nanoemulsion capable of being directly externally used for skin and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101947312A true CN101947312A (en) | 2011-01-19 |
CN101947312B CN101947312B (en) | 2012-08-15 |
Family
ID=43451020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010265116XA Expired - Fee Related CN101947312B (en) | 2010-08-26 | 2010-08-26 | Modified polyethylene glycol superoxide dismutase (mPEG-SOD) nanoemulsion capable of being directly externally used for skin and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101947312B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130209545A1 (en) * | 2012-01-19 | 2013-08-15 | Hybrid Medical, Llc | Topical therapeutic formulations |
CN106267173A (en) * | 2016-08-16 | 2017-01-04 | 福州大学 | A kind of Cu/Zn SOD nano-particle and preparation method and application |
KR101749665B1 (en) | 2014-10-21 | 2017-06-21 | 가톨릭대학교 산학협력단 | Composition for stabilizing EC-SOD and method of stabilizing EC-SOD using the same |
US10471131B2 (en) | 2012-01-19 | 2019-11-12 | Hybrid Medical, Llc | Topical therapeutic formulations |
CN116196458A (en) * | 2023-03-23 | 2023-06-02 | 南通大学 | Healing-promoting dressing for chronic wounds and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101214200A (en) * | 2008-01-21 | 2008-07-09 | 丁克祥 | Skin externally-applied liquid state and solid state kreotoxin (liushengtai) composite nano emulsion and preparation thereof |
WO2010036938A2 (en) * | 2008-09-26 | 2010-04-01 | Nanobio Corporation | Nanoemulsion therapeutic compositions and methods of using the same |
CN101791285A (en) * | 2010-04-13 | 2010-08-04 | 董萍 | Clausenamide composite nanometer emulsion for clearing facial age pigment (lipofuscin) and preparation method thereof |
-
2010
- 2010-08-26 CN CN201010265116XA patent/CN101947312B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101214200A (en) * | 2008-01-21 | 2008-07-09 | 丁克祥 | Skin externally-applied liquid state and solid state kreotoxin (liushengtai) composite nano emulsion and preparation thereof |
WO2010036938A2 (en) * | 2008-09-26 | 2010-04-01 | Nanobio Corporation | Nanoemulsion therapeutic compositions and methods of using the same |
CN101791285A (en) * | 2010-04-13 | 2010-08-04 | 董萍 | Clausenamide composite nanometer emulsion for clearing facial age pigment (lipofuscin) and preparation method thereof |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130209545A1 (en) * | 2012-01-19 | 2013-08-15 | Hybrid Medical, Llc | Topical therapeutic formulations |
US9238059B2 (en) | 2012-01-19 | 2016-01-19 | Hybrid Medical, Llc | Topical therapeutic formulations |
US9333242B2 (en) * | 2012-01-19 | 2016-05-10 | Hybrid Medical, Llc | Topical therapeutic formulations |
US10471131B2 (en) | 2012-01-19 | 2019-11-12 | Hybrid Medical, Llc | Topical therapeutic formulations |
US11446363B2 (en) | 2012-01-19 | 2022-09-20 | Hybrid Medical, Inc. | Topical therapeutic formulations |
US11622997B2 (en) | 2012-01-19 | 2023-04-11 | Hybrid Medical, Inc. | Topical therapeutic formulations |
US12053508B2 (en) | 2012-01-19 | 2024-08-06 | Hybrid Medical, Llc | Topical therapeutic formulations |
KR101749665B1 (en) | 2014-10-21 | 2017-06-21 | 가톨릭대학교 산학협력단 | Composition for stabilizing EC-SOD and method of stabilizing EC-SOD using the same |
CN106267173A (en) * | 2016-08-16 | 2017-01-04 | 福州大学 | A kind of Cu/Zn SOD nano-particle and preparation method and application |
CN106267173B (en) * | 2016-08-16 | 2019-08-09 | 福州大学 | A kind of Cu/Zn SOD nano particle and the preparation method and application thereof |
CN116196458A (en) * | 2023-03-23 | 2023-06-02 | 南通大学 | Healing-promoting dressing for chronic wounds and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN101947312B (en) | 2012-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6047207B2 (en) | Method and material for forming site-activated complex of biomolecule | |
CN101947312B (en) | Modified polyethylene glycol superoxide dismutase (mPEG-SOD) nanoemulsion capable of being directly externally used for skin and preparation method thereof | |
CN104922171B (en) | Use of extract of Chenopodium quinoa for preparing composition for promoting collagen production and resisting skin aging | |
US6461857B1 (en) | Producing water-soluble yeast extract by adding peroxide to growing yeast cells | |
Gibbons et al. | Vitamin K compounds in bacteria that are obligate anaerobes | |
WO2005017134A2 (en) | Isozyme of autoclavable superoxide dismutase (sod) derived from curcuma longa l | |
JP4401617B2 (en) | Cucumismelo extract coated and / or microencapsulated in a fat-soluble agent based on fatty substances | |
CN104717970A (en) | Glutathione-elevating compositions and uses thereof | |
SMOLINSKÁ et al. | Current status of the applications of conditioned media derived from mesenchymal stem cells for regenerative medicine | |
US9186406B2 (en) | Compositions containing nucleosides and manganese and their uses | |
EP0237398B1 (en) | Use of biologically active polypeptides and compositions containing them | |
CN101683149A (en) | Preparation of composition of reduced glutathione hormone, vitamin C and selenium compound | |
CN103122294B (en) | Wine containing SOD (Superoxide Dismutase) component and preparation method thereof | |
BEYDEMİR et al. | Purification of glucose 6-phosphate dehydrogenase from goose erythrocytes and kinetic properties | |
CN111840127B (en) | Free radical scavenger with anti-aging and sugar-blocking effects and preparation method thereof | |
An et al. | Toxicological evaluation of a probiotic-based delivery system for P8 protein as an anti-colorectal cancer drug | |
KR101252468B1 (en) | Cosmetics composition for skin troubles | |
KR101352565B1 (en) | Removing agent of hydrogen peroxide containing magnesium-protoporphyrin IX and method for eliminating hydrogen peroxide toxicity using it | |
Asgari et al. | Management of oxidative stress for cell therapy through combinational approaches of stem cells, antioxidants, and photobiomodulation | |
CN110227058A (en) | Pleiotrophic factor composition and its preparation method and application | |
Djahonkulovna | Analysis of Modern Pathomorphological Data Obtained in Experimental Studies | |
Ventiyaningsih et al. | The Effect of Moringa Oleifera Leaves Powder to Level of Serum Superoxide Dismutase (Sod), Lead (Pb), Zink (Zn) And Memory Function of Rat (Rattus Norvegicus) Wistar Strain Model of Autism That is Exposed by Pb | |
FR2827301A1 (en) | Enriching photosynthetic microorganisms with biologically active molecules, useful for delivering pharmaceuticals, by incubating cells in presence of the molecules | |
KR100749957B1 (en) | Antioxidant composition containing quercetin and vitamin c and functional food containing the same to inhibit and treat pesticide poisoning or diabetic microvascular complications | |
Roşca et al. | The influence of polyphenols of green walnut extract on zinc homeostasis and its role in the organism of breeding roosters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120815 |
|
CF01 | Termination of patent right due to non-payment of annual fee |